FDA Warns 5 Peptide Vendors: Who's Named, What Changes

The FDA posted five warning letters to peptide sellers on September 1, 2026. All five were signed on August 24, all came out of the Center for Drug Evaluation and Research, and all carry the same subject line: Unapproved New Drugs/Misbranded. The named companies are Peak Performance Peptides, Royal Peptides LLC, NuScience Peptides LLC, Peptide Partners LLC, and TXP Innovations LLC trading as Tex Peptides.

Two things make this set worth reading rather than filing. The first is that every one of the five was flagged over retatrutide — the same investigational triple agonist Eli Lilly took six sellers to court over three weeks earlier. The second is the rest of the compound list: alongside retatrutide and semaglutide sit tesamorelin, elamipretide and bremelanotide. That is a wider perimeter than the weight-loss-only framing most coverage of peptide enforcement has used this year.

Research-context information only. This article reports on federal agency correspondence and news coverage of it as published. A warning letter states the FDA's allegations and is not a court finding; none of the five companies has responded publicly as of writing. Nothing here is medical or legal advice. Retatrutide is an investigational molecule with no marketing approval in any country, and research-use-only material sold by peptide vendors is not FDA-approved for human use and has not been evaluated for safety, purity or potency as sold. Consult a licensed physician for personal medical decisions.

The five letters

The eight-day gap between signature and publication is routine — the FDA posts letters in weekly batches, so the September 1 posting date is when the action became public, not when it happened. Recipients had already been on notice for over a week by the time anyone outside the agency could read the letters.

Issuing all five on a single date, out of a single office, against a single lead compound is the part that reads as deliberate. This is a coordinated batch rather than five independent inspections that happened to land together.

The legal theory: the disclaimer is not the product

The interesting content in these letters is not that the FDA objects to unapproved peptides being sold. It is how the agency establishes that an unapproved peptide is being sold as a drug at all.

Every research-peptide vendor labels its catalogue research-use-only. The FDA's position across its 2026 peptide correspondence is that the label does not decide the question — the seller's own website does. Coverage of this batch quotes the agency saying that evidence obtained from each website established that the products are intended for human use, notwithstanding the sellers' claims that the material was strictly for laboratory research.

That reasoning is visible in more detail in an earlier letter from the same enforcement line. In the June 2026 letter to Wholesale Peptide, the FDA reproduced the seller's own product copy — statements that a compound "reduces chronic inflammation in the prostate," that research "can improve bladder control," references to named conditions — and concluded that language of that kind made the products drugs under sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act. A footnote addressed the disclaimer directly: the "research use only" wording did not displace what the rest of the labelling established. That letter asked for a written response within 15 business days.

So the operative variable is not what a vendor stocks. It is what a vendor's site says about what the compound does in a human body. Two sellers can list the identical vial and sit in very different positions depending on whether one of them published dosing guidance aimed at people, condition claims, or customer testimonials.

What changes for buyers

Very little changes mechanically, and it is worth being precise about that rather than dramatic.

On the five named companies. One appears in our vendor database: Royal Peptides. It has been marked not-recommended on this site since well before these letters, and it holds no placement on any comparison page — our Royal Peptides review records the reasoning. The other four — Peak Performance Peptides, NuScience Peptides, Peptide Partners and Tex Peptides — have never appeared in our offer database and are not vendors we have tracked or priced.

On the vendors we do list. None of the six recommended vendors on this site received a letter in this batch. Current vendor deals and coupon terms are unaffected, and no listing changed as a result of the September 1 posting.

On pending orders. A warning letter does not seize inventory, freeze accounts or halt shipments. It opens a correspondence window. The pattern from previous rounds is that the visible consequence arrives as catalogue editing — specific listings quietly coming down — rather than a closure notice. That is exactly what happened after the Lilly filings in August, where three defendants pulled their retatrutide pages within a day while continuing to trade everything else.

The signal actually worth watching is the same one that has predicted vendor outcomes better than any regulatory document for two years running: payment processing. Our record of which vendors shut down across 2025 and 2026 is largely a record of banking relationships ending, not of enforcement letters landing. Cards declining at checkout, a sudden switch to crypto or ACH as the only option, or a new processor name on the payment page are all faster indicators than a docket or a letter.

References

• FDA — Warning Letters database — index listing the five letters, each dated 08/24/2026, posted 09/01/2026, issuing office CDER, subject "Unapproved New Drugs/Misbranded."
• FDA — Warning Letter to Wholesale Peptide, 729447, 06/17/2026 — source for the agency's reasoning on research-use-only labelling, the FD&C Act sections cited, and the 15-business-day response window.
• Pharmaceutical Technology — FDA cracks down on online black market for weight loss peptides (September 2, 2026) — identifies the five recipients and the compounds named, including tesamorelin, elamipretide and bremelanotide.

Related Guides

• Retatrutide Buying Guide — vendor comparison and cost per mg for the compound at the centre of this batch.
• Tesamorelin Buying Guide — pricing and sourcing for one of the newly named compounds.
• SS-31 Buying Guide — the research-channel name for elamipretide.
• PT-141 Buying Guide — the research-channel name for bremelanotide.
• Peptide Vendors That Shut Down, 2025-2026 — the record showing processor loss, not enforcement letters, driving vendor exits.
• Lilly Sues 6 Retatrutide Sellers — the August civil litigation running parallel to this enforcement.
• Are Peptides Legal in the US? — how the compounding track and the research-supply track differ.
• Compare retatrutide vendors — live pricing across recommended vendors.
• Current vendor deals — active coupons across every recommended vendor.